ASSIST is driven by the devastating fact that 1 in 5 men and 1 in 6 women will develop cancer. Globally in 2018, 1 in 8 men and 1 in 10 women with cancer will die. If nothing changes, 2040 will see a 71.5% increase in cancer mortalities, dramatically worsening these numbers.
ASSIST is committed to finding safe and effective ways to treat cancer patients all over the world irrespective of their location, ability to pay and stage of cancer. We believe this is possible - think about how the dedicated work of the Global Fund for HIV/AIDS halved the death rate in 20 years!
ASSIST’s team is committed to make cancer a manageable illness for many, rather than treated like a fatal disease. We know it’s through innovation and disruption that transformation takes place. Cancer patients in the developing world face unique treatment access challenges that cannot be met by most of today’s approved cancer drugs. By addressing these heretofore insurmountable challenges, ASSIST expects to change the future of cancer treatment for this largely unserved population. Thereby set an example that can impact communities across the globe.
We believe the bold fuel for this change is NED-170, a combination therapy being developed by NED Biosystems (NED). A public benefit corporation, NED has committed to making NED-170 available to NGOs at cost for developing-world distribution upon regulatory approval.
Courtesy of Howard Hughes Medical Institute Biointeractive
ASSIST’s mission is simple: to foster Lab-to-Clinic™ therapies and diagnostics that dramatically improve treatment and detection of complex chronic diseases driven by angiogenesis – such as cancer.
(Angiogenesis plays a key role in the diseases comprising the majority of our nation’s most significant public health challenges—namely cancer, coronary artery disease, obesity, Alzheimer’s, Parkinson’s, diabetes, and 60+ additional chronic illnesses.)
Earlier Diagnosis, Comprehensive Treatments
ASSIST Medical Research Foundation supports advancing Lab-to-ClinicTM research that will improve treatments and earlier diagnosis of cancer
Our Response to
Every day, more and more citizens are being exposed to the Novel Coronavirus (COVID-19). It has brought our world to a standstill, and ASSIST cannot sit idly by and watch our loved ones and friends continue to be afflicted by this horrific pandemic.
ASSIST is committed to supporting initiatives to develop safe and effective treatments for COVID-19 and to make those treatments available in the developing world. This support may take the form of grants to other non-profit organizations or program-related investments in for-profit companies. For example, ASSIST is planning to make a program-related investment in NED Biosystems to support their efforts to test their investigational compound, NED-170.
The well-documented science behind NED-170 indicates that it may provide a double benefit for COVID-19 positive patients. 1. To inhibit disease progression for those afflicted. 2. To protect those who are exposed to COVID-19 from viral infection. NED-170 is currently awaiting an Emergency Use Authorization so that it may be administered to COVID-19 positive patients.
Our frontline workers are giving all of themselves to us, so ASSIST will respond in kind. ASSIST vows to help support clinical studies on preventing infection amongst our heroic healthcare workers and first responders.
After clinical trials are concluded, ASSIST is committed to supporting efforts to make this treatment available in the developing world.
ASSIST’s vision is that all COVID-19 patients will have access to this treatment in hopes of improving their quality-of-life, with low toxicity, and allowing them to remain productive members of their community. The need is urgent, and the time is now.
Through the support and donations of visionary donors, ASSIST can help achieve the goal of keeping COVID-19 at bay, and get the world moving forward without the fear of disease.
For More Information:
Please contact ASSIST with any questions here.